Compositions and methods for treating seizure disorders

Patent metadata

Field	Value
Publication number	US-2020297665-A1
Application number	US-202016881373-A
Country	US
Kind code	A1
Filing date	May 22, 2020
Priority date	Sep 30, 2016
Publication date	Sep 24, 2020
Grant date	—

Abstract

Functional analogs of fenfluramine are provided. The subject fenfluramine functional analogs find use in the treatment of a variety of diseases. For example, methods of treating epilepsy by administering a fenfluramine analog to a subject in need thereof are provided. Also provided are methods of treating a neurodegenerative disease in a subject in need thereof. Pharmaceutical compositions for use in practicing the subject methods are also provided.

First claim

1 . A method for treating a patient diagnosed with a form of refractory epilepsy selected from the group consisting of Dravet syndrome, Lennox-Gastaut syndrome, Doose syndrome, West syndrome, comprising:
administering an effective dose of a therapeutic agent, wherein the therapeutic agent comprises a compound active at one or more 5-HT receptor selected from the 5-HT1A receptor. the 5-HT1D receptor, the 5-HT2A receptor, and the 5-HT2C receptor.

2 .- 5 . (canceled)

6 . The method of claim 1 , wherein the therapeutic agent is active at to two or more targets.

7 . The method of claim 6 , wherein the therapeutic agent is active at the 5-HT1A receptor and further is active at the sigma-1 receptor.

8 . (canceled)

9 . The method of claim 1 , wherein the therapeutic agent is a compound according to the structure:

wherein
a. R1-R5 are each independently selected from H, OH, optionally substituted C1-4 alkyl, optionally substituted C1-3 alkoxy, optionally substituted C2-4 alkenyl, optionally substituted C2-4 alkynyl, halogen, amino, acylamido, CN, CF3, NO2, N3, CONH2, CO2R12, CH2OR12, NR12R13, NHCOR12, NHCO2R12, CONR12R13; C1-3 alkylthio, R12SO, R12SO2, CF3S, and CF3SO2;
b. R6 and R7 are each independently selected from H or optionally substituted C1-10alkyl, or R6 and R7 together constitute ═O or ═CH2;
c. R8 and R9 are each independently selected from H or optionally substituted C1-10alkyl;
d. R10, R11, R12, and R13 are each independently selected from H or optionally substituted C1-10 alkyl;
e. and wherein R1 and R8 may be joined to form a cyclic ring; or a pharmaceutically acceptable ester, amide, salt, solvate, prodrug, or isomer thereof,

with the proviso that when one of R8 and R9 is CH3, then at least one of R10 and R11 is optionally substituted C3-C10 cycloalkyl.

10 .- 18 . (canceled)

19 . The method of claim 1 , further wherein the therapeutic agent is at least one of:
(a) inactive at the 5-HT2B receptor; (b) a neutral agonist of the 5-HT2B receptor; and (c) an inverse agonist of the 5-HT2B receptor 5-HT2B receptor.

20 . (canceled)

21 . The method of claim 1 , wherein an effective dose of the therapeutic agent is administered in a pharmaceutically acceptable carrier.

22 . The method of claim 21 , wherein the pharmaceutical composition is a formulation adapted to a dosage forms selected from the group consisting of an oral dosage form, an intravenous dosage form, rectal dosage form, subcutaneous dosage form, and a transdermal dosage form.

23 . The method of claim 22 , wherein the oral dosage form selected from the group consisting of a liquid, a suspension, a tablet, a capsule, a lozenge, and a dissolving strip.

Assignees

• Zogenix International Ltd

Inventors

• Martin Parthena
• Boyd Brooks M
• Gammaitoni Arnold
• Galer Bradley S
• FARFEL Gail

Classifications

• A61K31/5375

  1,4-Oxazines, e.g. morpholine · CPC title

• A61K31/00

  Medicinal preparations containing organic active ingredients · CPC title

• A61P25/08

  Antiepileptics; Anticonvulsants · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• A61K31/137 Primary

  Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone} · CPC title